FSD Pharma IncCanadian Securities Exchange:HUGEView on NASDAQ
- LAST PRICE0.6400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6300/ 7
- Ask / Lots0.6400/ 121
- Open / Previous Close0.6400 / 0.6400
- Day Range
- 52 Week Range
- Volume30,898
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HUGE |
|---|---|---|
| 09:34 ET | 500 | 0.64 |
| 12:48 ET | 7500 | 0.65 |
| 01:12 ET | 1000 | 0.65 |
| 01:55 ET | 500 | 0.65 |
| 02:27 ET | 5500 | 0.65 |
| 02:40 ET | 11000 | 0.64 |
| 02:56 ET | 1500 | 0.63 |
| 03:27 ET | 3000 | 0.64 |
Apr 17, 2024
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products, from 8:03AM ET on Wednesday Apr 17, 2024 by Dow Jones
8:03AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 15, 2024
Apr 7, 2024
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency, from 10:56PM ET on Sunday Apr 07, 2024 by Dow Jones
10:56PM ET on Sunday Apr 07, 2024 by Dow Jones
Apr 1, 2024
FSD Pharma Announces Filing of Year-End 2023 Results, from 10:01PM ET on Monday Apr 01, 2024 by Dow Jones
10:01PM ET on Monday Apr 01, 2024 by Dow Jones
Mar 27, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
FSD Pharma Inc | 25.9M | -1.0x | --- |
Thiogenesis Therapeutics Corp | 35.9M | -8.7x | --- |
Aptose Biosciences Inc | 27.5M | -0.2x | --- |
Biomind Labs Inc | 28.0M | -14.0x | --- |
Helix Biopharma Corp | 40.1M | -6.2x | --- |
BioMark Diagnostics Inc | 26.4M | -16.3x | --- |
Company Information
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
Contact Information
- Headquarters
- First Canadian Place 100 King Street West, Suite 4000TORONTO, ON, Canada M5X 1A4
- Phone
- 416-854-8884
- Fax
- 416-854-8884
Executives
- Co-Chairman of the Board, Executive Director
- Anthony Durkacz
- Chief Executive Officer
- Zeeshan Saeed
- Chief Financial Officer
- Nathan Coyle
- Chief Operating Officer
- Donal Carroll
- Vice President - Quality of Lucid
- Kevin Cassidy
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 40.4M |
FSD Pharma Inc does not pay a dividend. | |
Beta | 0.98 |
EPS | $-0.64 |
Book Value | $0.46 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
